Abstract: Delpazolid (LCB01-0371) is a novel oxazolidinone derivative with a good safety profile for treating gram-positive pathogenic infections such as Mycobacterium abscessus, a highly pathogenic drug-resistant Mycobacterium. In this study, we evaluated the pharmacokinetics (PK) and pharmacodynamics (PD) of delpazolid after 14 days of multiple oral administration, using data from adult patients with pulmonary tuberculosis. 800 mg once a day, 400 mg twice a day, 800 mg twice a day, and 1200 mg once a day delpazolid for 14 days were tested in 63 patients with pulmonary tuberculosis. For PK blood collection, inpatient and outpatient scheduling were separately implemented. Plasma concentrations of delpazolid were measured at visits 2, 4, 6, and 8 in outpatients, and four sparse blood samples were measured in inpatients. PD models were sequentially fitted using individual PK parameter estimates obtained from PK compartmental models. For PK modeling, 180 plasma concentrations of delpazolid from 56 patients were included. A two-compartment mixed first- and zero-order absorption model best described the time course of plasma concentration. For the PD model, 448 bacterial titer data from 60 patients were used. The time course of bacterial titers (log 10 CFU/mL) was described by a model that consists of the growth and killing rate of bacteria with the sigmoid E max model. The PK-PD simulation suggested that the bacterial titers are the lowest on the 800 mg bid regimen among the four, consistent with observed data, as all regimens substantially decrease. In the dose-response relationship, the effectiveness of delpazolid was suggested.
(© 2024, The American College of Clinical Pharmacology.)
References: Singh B, Cocker D, Ryan H, Sloan DJ. Linezolid for drug‐resistant pulmonary tuberculosis. Cochrane Database Syst Rev. 2019;2019(3):CD012836. doi:10.1002/14651858.CD012836.pub2.
Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug‐resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893‐902. doi:10.1056/NEJMoa1901814.
Cho YS, Lim HS, Lee SH, Cho YL, Nam HS, Bae KS. Pharmacokinetics, pharmacodynamics, and tolerability of single‐dose oral LCB01‐0371, a novel oxazolidinone with broad‐spectrum activity, in healthy volunteers. Antimicrob Agents Chemother. 2018;62(7):se00451‐18. doi:10.1128/AAC.00451‐18.
Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta‐lactam for treatment of Gram‐positive bacterial infections: meta‐analysis of randomised controlled trials. Lancet Infect Dis. 2008;8(1):53‐66. doi:10.1016/S1473‐3099(07)70312‐2.
Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S. Linezolid in the treatment of multidrug‐resistant tuberculosis. Clin Infect Dis. 2010;50(1):49‐55. doi:10.1086/648675.
Kim TS, Choe JH, Kim YJ, et al. Activity of LCB01‐0371, a novel oxazolidinone, against Mycobacterium abscessus. Antimicrob Agents Chemother. 2017;61(9):e02752‐e02756. doi:10.1128/AAC.02752‐16.
Kim JS, Kim YH, Lee SH, et al. Early bactericidal activity of delpazolid (LCB01‐0371) in patients with pulmonary tuberculosis. Antimicrob Agents Chemother. 2022;66(2):e0168421. doi:10.1128/AAC.01684‐21.
Sunwoo J, Kim YK, Choi Y, et al. Effect of food on the pharmacokinetic characteristics of a single oral dose of LCB01‐0371, a novel oxazolidinone antibiotic. Drug Des Devel Ther. 2018;12:1707‐1714. doi:10.2147/DDDT.S155657.
Rajman I. PK/PD modelling and simulations: utility in drug development. Drug Discov Today. 2008;13(7‐8):341‐346. doi:10.1016/j.drudis.2008.01.003.
Choi Y, Lee SW, Kim A, et al. Safety, tolerability and pharmacokinetics of 21 day multiple oral administration of a new oxazolidinone antibiotic, LCB01‐0371, in healthy male subjects. J Antimicrob Chemother. 2018;73(1):183‐190. doi:10.1093/jac/dkx367.
Foti C, Piperno A, Scala A, Giuffrè O. Oxazolidinone antibiotics: chemical, biological and analytical aspects. Molecules. 2021;26(14):4280. doi:10.3390/molecules26144280.
Riad LE, Chan KK, Wagner WE Jr, Sawchuk RJ. Simultaneous first‐ and zero‐order absorption of carbamazepine tablets in humans. J Pharm Sci. 1986;75(9):897‐900. doi:10.1002/jps.2600750916.
Abrantes JA, Jönsson S, Karlsson MO, Nielsen EI. Handling interoccasion variability in model‐based dose individualization using therapeutic drug monitoring data. Br J Clin Pharmacol. 2019;85(6):1326‐1336. doi:10.1111/bcp.13901.
Peleg M, Corradini MG. Microbial growth curves: what the models tell us and what they cannot. Crit Rev Food Sci Nutr. 2011;51(10):917‐945. doi:10.1080/10408398.2011.570463.
Owen JS, Fiedler‐Kelly J. Chapter 10: Introduction to population Pharmacokinetic/Pharmacodynamic Analysis With Nonlinear Mixed Effects Models. Wiley; 2014:250‐252.
Processing Request
No Comments.